Vitality Watch

Dossier pubmed review 12-may-2026
Narrative review or expert overview without new data

What obgyns need to know about GLP-1 receptor agonists.

Key claim: GLP-1 receptor agonists and dual agonists deliver 15–21% weight loss and PCOS metabolic/reproductive benefits, requiring OBGYN counseling on contraception, preconception discontinuation, and individualized perioperative management.

Abstract

PURPOSE OF REVIEW: Obstetricians and gynecologists increasingly encounter patients using glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide agonists. This review synthesizes evidence on these agents, focusing on their relevance in women’s health. RECENT FINDINGS: GLP-1 receptor agonists and dual agonists achieve 15-21% body weight reduction in phase 3 trials, with tirzepatide demonstrating superior efficacy compared to semaglutide. Key populations of interest include patients with polycystic ovary syndrome (PCOS), pregnant patients, and those undergoing gynecologic surgery. In women with PCOS, meta-analyses confirm improvements in insulin resistance, androgen levels, and ovulation rates. Tirzepatide significantly delays gastric emptying, prompting manufacturer guidance to use backup contraception for 4 weeks after initiation or dose escalation. Emerging human cohort studies of inadvertent early pregnancy exposure report no increased risk of major congenital malformations, providing preliminary reassurance despite animal teratogenicity data. Perioperative guidance has evolved from blanket discontinuation to individualized, risk-stratified approaches. SUMMARY: GLP-1 receptor agonists offer benefits across the lifespan, with promising applications in PCOS and preconception optimization. Reproductive-aged women need counseling regarding contraception and preconception discontinuation. Knowledge gaps include the need for pregnancy registries. Obstetrician-gynecologists will increasingly encounter these therapies and must navigate evolving evidence regarding their safety, efficacy, and clinical implications.

Why this matters

GLP-1 receptor agonists and dual agonists deliver 15–21% weight loss and PCOS metabolic/reproductive benefits, requiring OBGYN counseling on contraception, preconception discontinuation, and individualized perioperative management.

Source

Link

Briefing card

What obgyns need to know about GLP-1 receptor agonists.
Stage: review · pubmed · 12-may-2026

GLP-1 receptor agonists and dual agonists deliver 15–21% weight loss and PCOS metabolic/reproductive benefits, requiring OBGYN counseling on contraception, preconception discontinuation, and individualized perioperative management.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1097/GCO.0000000000001116

build build 880 · 2bcef25 · 2026-11-18